Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2
- PMID: 39275006
- PMCID: PMC11397024
- DOI: 10.3390/molecules29174158
Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2
Abstract
The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and selective CSNK2 inhibitors with good pharmacokinetic properties are required. Inhibitors based on the pyrazolo[1,5-a]pyrimidine scaffold possess outstanding potency and selectivity for CSNK2, but bioavailability and metabolic stability are often challenging. By strategically installing a fluorine atom on an electron-rich phenyl ring of a previously characterized inhibitor 1, we discovered compound 2 as a promising lead compound with improved in vivo metabolic stability. Compound 2 maintained excellent cellular potency against CSNK2, submicromolar antiviral potency, and favorable solubility, and was remarkably selective for CSNK2 when screened against 192 kinases across the human kinome. We additionally present a co-crystal structure to support its on-target binding mode. In vivo, compound 2 was orally bioavailable, and demonstrated modest and transient inhibition of CSNK2, although antiviral activity was not observed, possibly attributed to its lack of prolonged CSNK2 inhibition.
Keywords: CSNK2; SARS-CoV-2; antiviral; fluorination; pyrazolo[1,5-a]pyrimidine; β-coronavirus.
Conflict of interest statement
Authors Jason W. Brown, Edcon Chang were employed by the company Takeda Development Center Americas, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
References
-
- WHO COVID-19 Dashboard. [(accessed on 22 April 2024)]; Available online: https://covid19.who.int/
-
- Payne S. Viruses. Elsevier; Amsterdam, The Netherlands: 2017. Family Coronaviridae; pp. 149–158.
-
- Richman D.D., Nathanson N. Viral Pathogenesis. Elsevier; Amsterdam, The Netherlands: 2016. Antiviral Therapy; pp. 271–287.
-
- Ryu W.-S. Molecular Virology of Human Pathogenic Viruses. Elsevier; Amsterdam, The Netherlands: 2017. Antiviral Therapy; pp. 367–381.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources